기저 인슐린 시장 : 유형별, 투여 디바이스별, 적응증별, 연령층별, 유통 채널별, 지역별
Basal Insulin Market, By Type, By Delivery Device, By Indication, By Age Group, By Distribution Channel, By Geography
상품코드
:
1741457
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
기저 인슐린 시장은 2025년 196억 5,000만 달러, 2032년에는 378억 1,000만 달러에 이를 것으로 예측되며, 2025-2032년 CAGR 9.8%를 보일 것으로 예측됩니다.
| 보고서 범위 |
보고서 상세 |
| 기준 연도 |
2024 |
2025년 시장 규모 |
196억 5,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간(2025-2032년) CAGR |
9.80% |
2032년 가치 예측 |
378억 1,000만 달러 |
기저 인슐린은 장시간 작용하는 인슐린의 일종으로 당뇨병 환자의 혈당을 조절하기 위해 밤낮으로 인슐린을 안정적으로 방출하는 인슐린의 일종입니다. 일반적으로 인슐린 요법이 필요한 1형 당뇨병 환자 또는 2형 당뇨병 환자에게 처방됩니다. 기저 인슐린은 식사와 식사 사이 또는 공복 시 안정적인 혈당를 유지하여 최적의 당뇨병 관리의 기초를 제공합니다.
세계 기저 인슐린 시장은 전 세계 당뇨병 유병률 증가에 힘입어 큰 폭으로 성장하고 있습니다. 국제당뇨병연맹에 따르면 성인 당뇨병 환자 수는 2045년까지 7억 명에 달할 것으로 예상되고 있습니다. 이러한 당뇨병 환자 증가는 당뇨병 관리에 필수적인 요소인 기저 인슐린에 대한 수요를 증가시키고 있습니다.
시장 역학:
기저 인슐린 시장은 몇 가지 요인에 의해 주도되고 있습니다. 당뇨병, 특히 2형 당뇨병의 유병률 증가는 시장의 주요 촉진요인입니다. 좌식 생활, 불규칙한 식습관, 비만과 같은 건강에 해로운 생활 습관이 전 세계 당뇨병 유병률 증가에 기여하고 있습니다. 이에 따라 기저 인슐린에 대한 수요가 크게 증가할 것으로 예측됩니다.
또한, 인슐린 치료 기술의 발전도 시장 성장의 원동력이 되고 있습니다. 약동학적 특성이 개선된 인슐린 유사체의 개발로 기저 인슐린 치료의 효과와 편의성이 크게 향상되었습니다. 이러한 발전은 혈당 조절을 개선하고 저혈당 위험을 감소시켰습니다.
예를 들어, 2023년 10월 23일, 임상 단계에 있는 바이오 제약사 아드시아는 중국 본사를 둔 제약사 통화동바오제약(Tonghua Dongbao Pharmaceutical Co., Ltd.)이 파트너인 인슐린 리스프로와 인슐린 글라진을 포함한 인슐린 리스프로와 인슐린 글라진을 포함한 바이오 샤페론 콤보 THDB0207 제제에 대해 실시한 3개의 임상시험에서 좋은 결과를 얻었습니다고 발표했습니다. 이 세 가지 시험에서 BC 콤보는 장시간 지속형 인슐린과 속효성 인슐린의 성질을 모두 갖춘 유용한 인슐린임을 보여주었습니다. 그 결과, 식후 및 공복 시 혈당 조절을 보장할 수 있습니다.
그러나 기저 인슐린 시장의 성장을 저해하는 요인도 있습니다. 높은 인슐린 치료 비용, 특정 지역의 제한된 의료 서비스 접근성 등이 이러한 장벽 중 일부입니다. 또한, 인슐린 제조 및 유통에 대한 엄격한 규제 요건으로 인해 시장 기업들은 어려움을 겪고 있습니다.
이러한 도전에도 불구하고 기저 인슐린 시장은 몇 가지 성장 기회를 가지고 있습니다. 노인 인구 증가와 당뇨병 관리의 중요성에 대한 인식이 높아짐에 따라 시장 성장의 원동력이 될 것으로 예측됩니다. 또한, 스마트 인슐린 전달 시스템의 개발과 당뇨병 관리에서 디지털 기술의 통합은 시장 기업들이 개척해야 할 새로운 길을 제시하고 있습니다.
본 조사의 주요 특징
- 세계의 기저 인슐린 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 2025-2032년까지의 예측 기간 동안 시장 규모와 연평균 성장률(CAGR)을 조사하여 상세하게 분석하였습니다.
- 다양한 부문에 걸친 잠재적 수익 성장 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 기저 인슐린 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 실적, 전략에 따라 정리하여 전해드립니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 기저 인슐린 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 기저 인슐린 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 발매 및 승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
제4장 세계의 기저 인슐린 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측 분석
- 경제에 대한 영향
제5장 세계의 기저 인슐린 시장, 유형별, 2020년-2032년
- Glargine
- Detemir
- Degludec
제6장 세계의 기저 인슐린 시장, 투여 디바이스별, 2020년-2032년
제7장 세계의 기저 인슐린 시장, 적응증별, 2020년-2032년
제8장 세계의 기저 인슐린 시장, 연령층별, 2020년-2032년
제9장 세계의 기저 인슐린 시장, 유통 채널별, 2020년-2032년
제10장 세계의 기저 인슐린 시장, 지역별, 2020년-2032년
- 북미
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 일본
- 인도
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제11장 경쟁 구도
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- United Laboratories
- Merck
- Wockhardt
- Julphar Diabetes
- Medtronic
- Beta Bionics
- Zealand Pharma
- MannKind
- Peptron
- Dexcom
- Senseonics
- Medtrum Technologies
- SOOIL Development
- Semma Therapeutics
제12장 섹션
LSH
영문 목차
Basal Insulin Market is estimated to be valued at USD 19.65 Bn in 2025 and is expected to reach USD 37.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 19.65 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
9.80% |
2032 Value Projection: |
USD 37.81 Bn |
Basal insulin is a type of long-acting insulin that provides a steady release of insulin throughout the day and night to control blood sugar levels in individuals with diabetes. It is typically prescribed for individuals with type 1 diabetes or type 2 diabetes who require insulin therapy. Basal insulin helps maintain stable blood sugar levels between meals and during periods of fasting, providing a foundation for optimal diabetes management.
The global basal insulin market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation, the number of adults with diabetes is expected to reach 700 million by 2045. This rise in diabetes cases is fueling the demand for basal insulin, as it is an essential component of diabetes management.
Market Dynamics:
The basal insulin market is driven by several factors. The rising prevalence of diabetes, particularly type 2 diabetes, is a key driver for the market. Unhealthy lifestyle habits, such as sedentary behavior, poor diet, and obesity, are contributing to the increasing incidence of diabetes globally. As a result, the demand for basal insulin is expected to rise significantly.
In addition, advancements in insulin therapy technologies are also driving the market growth. The development of insulin analogs, which have improved pharmacokinetic properties, has significantly enhanced the efficacy and convenience of basal insulin therapy. These advancements have led to better glycemic control and reduced risks of hypoglycemia.
For instance, on October 23, 2023, Adocia, a biopharmaceutical company in the clinical stage, announced that Tonghua Dongbao Pharmaceutical Co. Ltd., a pharmaceutical company based in China, is its partner and has released positive results from three clinical studies conducted on the BioChaperone Combo THDB0207 formulation, which contains insulin lispro and insulin glargine. These three studies showed that BC Combo is a useful insulin that combines the qualities of both long-acting and rapid-acting insulin. As a result, it can guarantee glycemic control during the postprandial and fasting periods.
However, there are certain restraints that may hinder the growth of the basal insulin market. The high cost of insulin therapy and limited access to healthcare in certain regions are some of the barriers. Additionally, the stringent regulatory requirements for insulin production and distribution pose challenges for market players.
Despite these challenges, there are several opportunities for growth in the basal insulin market. The increasing geriatric population, as well as the growing awareness about the importance of diabetes management, are expected to drive the market growth. Furthermore, the development of smart insulin delivery systems and the integration of digital technologies in diabetes management present new avenues for market players to explore.
Key Features of the Study:
- This report provides an in-depth analysis of the global basal insulin market including market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, with 2024 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- Key players in the global basal insulin market are profiled based on company highlights, product portfolio, key highlights, financial performance, and strategies
- Key companies covered in this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Gan & Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories, Merck, Wockhardt, Julphar Diabetes, Medtronic, Beta Bionics, Zealand Pharma, MannKind, Peptron, Dexcom, Senseonics, Medtrum Technologies, SOOIL Development, and Semma Therapeutics
- Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
- The global basal insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal insulin market
Basal Insulin Market Segmentation:
- By Type
- Glargine
- Detemir
- Degludec
- By Delivery Device
- Syringes
- Pens
- Pumps
- Others (Inhalers, Patches)
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- By Age Group
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- United Laboratories
- Merck
- Wockhardt
- Julphar Diabetes
- Medtronic
- Beta Bionics
- Zealand Pharma
- MannKind
- Peptron
- Dexcom
- Senseonics
- Medtrum Technologies
- SOOIL Development
- Semma Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Basal Insulin Market, By Type
- Global Basal Insulin Market, By Delivery Device
- Global Basal Insulin Market, By Indication
- Global Basal Insulin Market, By Age Group
- Global Basal Insulin Market, By Distribution Channel
- Global Basal Insulin Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising prevalence of diabetes, particularly type 2 diabetes
- High cost of insulin therapy
- Increasing geriatric population
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Basal Insulin Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Basal Insulin Market, By Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Glargine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Detemir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Degludec
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Basal Insulin Market, By Delivery Device, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Pens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Pumps
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others (Inhalers, Patches)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Basal Insulin Market, By Indication, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global Basal Insulin Market, By Age Group, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Global Basal Insulin Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
10. Global Basal Insulin Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
11. Competitive Landscape
- Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biocon
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gan & Lee Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Tonghua Dongbao Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- United Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Wockhardt
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Julphar Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Medtronic
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beta Bionics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zealand Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- MannKind
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Peptron
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Dexcom
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Senseonics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Medtrum Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- SOOIL Development
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Semma Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
12. Section
- Research Methodology
- About us
관련자료
